MRC1 and cancer: Consistent with single-cell transcriptome analysis, inhibition of ASH1L in cancer cells dramatically decreased TAMs with pro-tumoral phenotype (F4/80+CD206+) and led to an increase in tumor-infiltrating monocytes (Ly6c+) in the bone niche (Fig. 5h and Supplementary Fig. 7e).